行情

ARCT

ARCT

Arcturus医疗
NASDAQ

实时行情|Nasdaq Last Sale

51.81
-7.10
-12.05%
交易中 12:32 08/11 EDT
开盘
57.15
昨收
58.91
最高
57.43
最低
50.52
成交量
68.50万
成交额
--
52周最高
63.45
52周最低
8.51
市值
12.37亿
市盈率(TTM)
-21.6506
分时
5日
1月
3月
1年
5年

分析师评级

11位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测ARCT价格均价为62.40,最高价位80.00,最低价为18.00。

EPS

ARCT 新闻

更多
Arcturus Therapeutics Announces It Has Initiated Dosing Of Its Coronavirus STARR mRNA Vaccine Candidate, LUNAR-COV19 In Phase 1/2 Study
Benzinga · 4小时前
Arcturus Therapeutics Announces It Has Initiated Dosing Of Its Coronavirus STARR mRNA Vaccine Candidate, LUNAR-COV19 In Phase 1/2 Study
Benzinga · 4小时前
Raymond James Maintains Outperform on Arcturus Therapeutics, Raises Price Target to $79
Raymond James maintains Arcturus Therapeutics (NASDAQ:ARCT) with a Outperform and raises the price target from $72 to $79.
Benzinga · 4小时前
Arcturus Therapeutics (ARCT) Reports Q2 Loss, Misses Revenue Estimates
Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of -3.77% and -54.31%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 19小时前
Arcturus Therapeutics Q2 EPS $(0.55), Inline, Sales $2.32M Miss $3.54M Estimate
Arcturus Therapeutics (NASDAQ:ARCT) reported quarterly losses of $(0.55) per share which met the analyst consensus estimate. This is a 685.71 percent decrease over losses of $(0.07) per share from the same period last
Benzinga · 20小时前
Arcturus Therapeutics Announces Second Quarter 2020 Financial Results and Provides a Corporate Update
COVID-19 STARR™ mRNA vaccine candidate, ARCT-021 (LUNAR-COV19) has initiated Phase 1/2 clinical study with Duke-NUS Medical School; Dosing anticipated imminently, initial data expected Q4 ARCT-810 (LUNAR-OTC), mRNA therapeutic candidate for ornithine transcar
GlobeNewswire · 20小时前
Why Earnings Season Could Be Great for Arcturus Therapeutics (ARCT)?
Arcturus Therapeutics (ARCT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Zacks · 4天前
Arcturus Therapeutics Appoints Lance Kurata as Chief Legal Officer
Nationally recognized leader in corporate life sciences transactionsSAN DIEGO, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on
GlobeNewswire · 5天前

所属板块

生物技术和医学研究
-0.69%
制药与医学研究
-0.01%

热门股票

代码
价格
涨跌幅

ARCT 简况

Arcturus Therapeutics Ltd是一家核糖核酸(RNA)药物公司。该公司拥有脂质激活和解锁的核单体试剂修饰RNA(月球)脂质介导的递送和解锁的核单体试剂(UNA)技术,包括UNA低聚物。该公司的多种RNA治疗方案包括治疗罕见疾病、乙型肝炎、非酒精性脂肪性肝炎(NASH)、囊性纤维化和疫苗。该公司的多功能RNA治疗平台可应用于多种类型的RNA药物,包括小干扰RNA、信使RNA、复制子RNA、反义RNA、microRNA和基因编辑治疗。该公司的UNA技术可用于针对人类基因组中的单个基因,以及用于治疗目的的病毒基因和其他物种。
展开

微牛提供Arcturus Therapeutics Holdings Inc(NASDAQ-ARCT)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的ARCT股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易ARCT股票基本功能。